RxDoctor Payments Data

Heather Landau, MD

Hematology & Oncology · New York, NYNPI 1689889578

Payments from drug & device makers

$1,520,238in general payments, 2019–2025

Across 197 payments — averaging $7716.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Takeda Pharmaceuticals U.S.A., Inc.$585K
  • AstraZeneca$508K
  • Janssen Research & Development, LLC$274K
  • AbbVie$116K
  • Sanofi$10K
  • Pfizer$7K
  • plus $20K from 9 others
$831in research payments, 2019–2025

Across 2 payments — averaging $415.63 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Takeda Pharmaceuticals U.S.A., Inc.$781
  • AbbVie$50

What the payments were for

  • Consulting fees$42,27380%
  • Speaking & faculty fees$9,20817%
  • Travel & lodging$2861%
  • Food & beverage$8472%
  • Education$120%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,520,238 in reported general payments places this provider in the 90th percentile of 967 hematology & oncology providers in New York.

See all hematology & oncology providers in New York

Medicare billing

Part B allowed, 2024
$81,036
Medicare patients
199
Services billed
539

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VenclextaVenetoclax30$366,278
Lenalidomide12$122,590
Atovaquone11$16,991
Acyclovir218$3,835
Colesevelam Hcl13$2,108
ValacyclovirValacyclovir Hcl20$1,793
Enoxaparin Sodium12$1,325
Ondansetron Hcl12$1,123
Pantoprazole Sodium38$718
Potassium Chloride17$257
Allopurinol24$232
Duloxetine Hcl16$218
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim28$208
Amlodipine Besylate20$205
Losartan Potassium12$194

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVenclexta$116,447$366,27830 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 967 hematology & oncology providers in New York.

Other hematology & oncology in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →